Incheon City Takes off as Culture and Tourism Industry Hub in Northeast Asia with IFEZ’s Yeongjong Resort Complex Cluster
10.12.2019 15:00:00 EET | Business Wire | Press release
With rich tourism infrastructure and resources, including the world’s top-level Incheon International Airport, Ganghwa Island, open port area, and multiple islands, the Incheon Metropolitan City government plans to take off as a hub of culture and tourism industry in Northeast Asia through the Yeongjong-do Integrated Resort Cluster Project.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191210005029/en/
Incheon City plans to take off as a hub of culture and tourism industry in Northeast Asia through the Yeongjong-do Integrated Resort Cluster Project. Yeongjong International Town, where the Incheon International Airport is located, continues to expand cultural and tourism facilities. The first resort complex in Korea, the Paradise City comprises a 5-star hotel, the largest foreigners-only casino in Korea, and a convention hall that can accommodate 1,600 persons opened in 2017. To open it in 2021, the Caesars Resort Complex is under construction in Yeongjong-do by Caesars Entertainment. It will consist of a luxury hotel with over 700 rooms, casino for foreigners only, convention facilities, live entertainment performing hall, signature spa and a swimming pool. Adjacent to the Incheon International Airport, the Inspire Resort Complex is under construction led by Mohegan Gaming and Entertainment to open in 2022. (Photo: Business Wire)
Yeongjong International Town, where the Incheon International Airport is located, continues to expand cultural and tourism facilities, such as luxurious 5-star hotels, foreigners-only casinos, convention installations, spas, theme parks and more.
Having opened in April 2017 as the first resort complex in Korea, the ‘Paradise City’ comprises a 5-star hotel with 711 rooms, the largest foreigners-only casino in Korea, and a convention hall that can accommodate 1,600 persons. From September 2018, it has been operating a boutique hotel with 58 suite rooms, spa blended with Korean dry sauna culture, the largest recreation club in Northeast Asia, and an art exhibition space. In March 2019, it opened the Wonder Box, an indoor theme park with the concept of ‘amusement park in the evening’, presenting enjoyment both to foreign and local visitors.
To open it in 2021, the Caesars Resort Complex is under construction in Yeongjong-do by Caesars Entertainment headquartered in Las Vegas. The Caesars Resort Complex will consist of a luxury hotel with over 700 rooms, casino for foreigners only, convention facilities, live entertainment performing hall, signature spa and a swimming pool.
Adjacent to the Incheon International Airport, the Inspire Resort Complex is under construction led by Mohegan Gaming and Entertainment (MGE), the owner of Mohegan Sun casino located in Connecticut, to open in 2022. The resort complex will include a luxury hotel with over 1,250 rooms, foreigners-only casino, and indoor and outdoor theme parks. It will also operate a performing facility (arena) that can accommodate 15,000 audiences, staging Las Vegas-level fantastic performances all year round. It is expected to significantly contribute to spreading the Korean Wave.
The Incheon Free Economic Zone Authority expects the resort complex businesses to generate over 20,000 new jobs and production inducement effect of approximately KRW2 trillion (USD1680 million) annually. It also expects that the resort complex industry will conspicuously contribute to invigorating the regional economy and development of the MICE industry.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191210005029/en/
Contact information
Incheon Metropolitan City
Sang Kon Park
+82 32-440-3052
sangkon7@korea.kr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom